CADD522 protected bone and reduced fat in mice; human effects remain unknown
Over eight weeks, CADD522 improved bone volume and microarchitecture while lowering fat measures in mice whose ovaries were removed to model post-menopausal bone loss. The efficacy groups contained only eight mice each. Rat and dog studies showed oral bioavailability, but rapid clearance remains a constraint; short-term animal tolerability does not establish safety or osteoporosis treatment in people.
Science··Night
Bone and fat measures changed together
Mice whose ovaries had been removed to model post-menopausal bone loss received CADD522 at 25 milligrams per kilogram three times weekly for eight weeks. In the npj Drug Discovery study covered by Gazeta.ru and Metrópoles, treatment improved bone volume and internal bone microarchitecture. A marker associated with bone formation rose, while a bone-resorption marker did not change. Peripheral and bone-marrow fat also fell, and treated animals weighed less than controls despite eating the same amount. The findings show bone and lipid metabolism changing together in one animal model.[1], [2]
Each efficacy group contained eight mice
The efficacy comparisons used eight mice per group. That sample cannot establish how reliably the differences in bone volume, microarchitecture and fat would persist in larger populations. The model itself is not the whole of human menopause: removing the ovaries reproduces some bone consequences of oestrogen loss. Metrópoles explicitly keeps the research at an early stage and says stronger studies, including work in humans, are needed. CADD522 therefore cannot be described as treating osteoporosis or menopause-related weight gain in people.[2], [1]
Oral exposure is possible, but clearance is rapid
Pharmacokinetic experiments found oral bioavailability of about 52% in rats and 67% in dogs. That shows the compound can enter circulation in two species, but rapid clearance, also highlighted by Gazeta.ru, constrains how long an effective exposure might be maintained. Short-term tolerability in rats and dogs is not a substitute for evidence of human safety. Human tissue may also metabolise the compound at a different rate from rodent tissue, leaving dose and exposure uncertain. The next step is therefore to measure these pharmacological limits, not to present the mouse efficacy result as a human outcome.[1], [2]
